Exam Details
Subject | pharmacoepidmiology and pharmacoeconomics | |
Paper | ||
Exam / Course | pharm d (6–ydc) | |
Department | ||
Organization | G. Pulla Reddy College Of Pharmacy | |
Position | ||
Exam Date | September, 2017 | |
City, State | telangana, hyderabad |
Question Paper
FACULTY OF PHARMACY
Pharm. D. YDC) V Year (Main) Examination, September 2017
Subject: Pharmacoepidemiology and Pharmacoeconomics
Time: 3 Hours Max.Marks: 70
Note: Answer all questions from Part A. Answer any five questions from Part B.
PART A (10x2 20 Marks)
1. Define cost of illness. 2
2. What do you mean by cost minimization analysis? 2
3. Define cost utility analysis. 2
4. What do you mean by pharmacoepideomiology? 2
5. Mention various factors to be considered in evaluating pharmacoepideomiological
study. 2
6. What do you mean by Cochrane reviews? 2
7. How do you measure medication adherence? 2
8. Write a note on meta analysis. 2
9. Define teratology reports. 2
10. Mention major quality of life domains. 2
PART B (5x10 50 Marks)
11. Describe aims, applications of pharmacoepidemiology. Add a note on the origin
and evolution. 10
12. Describe in detail medication adherence measurement. Add a note on DDD. 10
13. Write notes on measurement of risk, attributable risk and relative risk. 10
14. Explain various pharmacoepiemiological methods with the help of case studies. 10
15.(a) Explain in detail developing a formulary list and formulary management? 7
Short note on teratology reports. 3
16. What are the sources of data for pharmacoepidemiological studies? 10
17. What do you mean by pharmacoepidemiological studies in hospital setup and
add a note on vaccine safety? 10
18. What are various pharmacoeconomic methods of evaluation and explain in detail
with the help of case studies. 10
Pharm. D. YDC) V Year (Main) Examination, September 2017
Subject: Pharmacoepidemiology and Pharmacoeconomics
Time: 3 Hours Max.Marks: 70
Note: Answer all questions from Part A. Answer any five questions from Part B.
PART A (10x2 20 Marks)
1. Define cost of illness. 2
2. What do you mean by cost minimization analysis? 2
3. Define cost utility analysis. 2
4. What do you mean by pharmacoepideomiology? 2
5. Mention various factors to be considered in evaluating pharmacoepideomiological
study. 2
6. What do you mean by Cochrane reviews? 2
7. How do you measure medication adherence? 2
8. Write a note on meta analysis. 2
9. Define teratology reports. 2
10. Mention major quality of life domains. 2
PART B (5x10 50 Marks)
11. Describe aims, applications of pharmacoepidemiology. Add a note on the origin
and evolution. 10
12. Describe in detail medication adherence measurement. Add a note on DDD. 10
13. Write notes on measurement of risk, attributable risk and relative risk. 10
14. Explain various pharmacoepiemiological methods with the help of case studies. 10
15.(a) Explain in detail developing a formulary list and formulary management? 7
Short note on teratology reports. 3
16. What are the sources of data for pharmacoepidemiological studies? 10
17. What do you mean by pharmacoepidemiological studies in hospital setup and
add a note on vaccine safety? 10
18. What are various pharmacoeconomic methods of evaluation and explain in detail
with the help of case studies. 10
Other Question Papers
Subjects
- biology
- biopharmaceutics & pharmacokinetics
- biostatistics & research methodology
- clinical & pharmacokinetics pharmacotherapeutic drug monitoring
- clinical pharmacokinetics and pharmacotherapeutic drug monitoring
- clinical pharmacy
- clinical research
- clinical toxicology
- community pharmacy
- hospital pharmacy
- human anatomy and physiology
- medicinal biochemistry
- medicinal chemistry
- pathophysiology
- pharmaceutical analysis
- pharmaceutical formulations
- pharmaceutical inorganic chemistry
- pharmaceutical jurisprudence
- pharmaceutical microbiology
- pharmaceutical organic chemistry
- pharmaceutics
- pharmacoepidmiology and pharmacoeconomics
- pharmacognosy & phytopharmaceuticals
- pharmacology – i
- pharmacology – ii
- pharmacotherapeutics – i
- pharmacotherapeutics – iii
- pharmacotherapeutics-ii